遠大醫藥(00512.HK)斥最多7,200萬美元收購美國FastWave Medical
遠大醫藥(00512.HK)公布,與美國FastWave Medical簽署一系列投資及戰略合作協議,將分階段以最多共7,200萬美元為代價取得FastWave 100%的股權;另外將投入最多800萬美元,支持和合作進行開發用作治療中、重度動脈鈣化的創新醫療器械血管內震波鈣化處理系統。
公司表示,目前中國治療血管內鈣化病變的產品依賴於進口,存在著巨大的未被滿足的臨床需求,在相關條件獲得滿足後預期FastWave可成為旗下心腦血管精準介入器械領域的全資附屬公司及海外高端創新醫療器械研發平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.